ras-p21-induced cell transformation: Unique signal transduction pathways and implications for the design of new chemotherapeutic agents

Cancer Investigation

Volumn 18, Issue 1, 2000, Pages 39-50

  Pincus, Matthew R ^a,b   Brandt Rauf, Paul W ^c   Michl, Joseph ^b   Carty, Robert P ^a,b   Friedman, Fred K ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P21; RAS PROTEIN;

ANIMAL CELL; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSOL; DRUG DESIGN; DRUG TARGETING; MITOGENESIS; MOUSE; NONHUMAN; ONCOGENE RAS; OOCYTE MATURATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033950650     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009023061     Document Type: Review

References (57)

1. Barbacid M: ras genes. Annu Rev Biochem 56:779-827, 1987.
2. Stacey DW, Kung H-F: Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein. Nature 310:508-511, 1984.
3. Birchmeier C, Broek D, Wigler M: ras proteins can induce meiosis in Xenopus oocytes. Cell 43:615-621, 1985.
4. Almoguerra C, Shibata D, Forrester K, et al: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:813-815, 1988.
5. Forester K, Almoguerra C, Han K, et al: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327:298-303, 1987.
6. Pincus MR, Brandt-Rauf PW, Nostro D: Cell biology and early tumor detection. In: Clinical Diagnosis and Management by Laboratory Methods, 19th ed., edited by JB Henry, Philadelphia, W.B. Saunders, 1996, pp 310-321.
7. Willumsen BM, Christensen A, Humbert NL, et al: The p21 ras C-terminus is required for transformation and membrane association. Nature 310:583-586, 1984.
8. Stacey DW, Feig LA, Gibbs JB: Dominant inhibitory ras mutants selectively inhibit the activity of either cellular or oncogenic ras. Mol Cell Biol 11:4053-4064, 1991.
9. Manne V, Ricca CS, Brown JG, et al: ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analogue inhibitors of farnesyltransferase. Drug Dev Res 34:121-137, 1995.
10. Chung DL, Joran A, Friedman FK, et al: Evidence that oocyte maturation induced by an oncogenic ras p21 protein and insulin is mediated by overlapping yet distinct mechanisms. Exp Cell Res 203:329-335, 1992.
11. deSolms SJ, Deana AA, Giuliani EA, et al: Pseudodipeptide inhibitors of protein farnesyltransferase. J Med Chem 38:3967-3971, 1995.
12. James GL, Goldstein GL, Brown MS, et al: Benzodiarepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 260:1937-1942, 1993.
13. ras interfere with insulin-induced gene expression. Mol Cell Biol 11:5963-5967, 1991.
14. Chardin P, Camonis JH, Gale NW, et al: Human SOS1: a guanine nucleotide exchange factor for ras that binds to Grb2. Science 260:1338-1343, 1993.
15. Willumsen BW, Papageorge AG, Kung H-F, et al: Mutational analysis of a ras catalytic domain. Mol Cell Biol 6:2646-2654, 1986.
16. Bokoch GM: Biology of the rap proteins, members of the ras superfamily of GTP-binding proteins. Biochem J 289:17-24, 1993.
17. Nassar N, Horn G, Herrmann C, et al: The 2.2 Å crystal structure of the RAS-binding domain of the serine/threonine kinase c-Raf-1 in complex with Rap-1A and a GTP analogue. Nature 375:554-560, 1995.
18. Trahey M, McCormick F: A cyloplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238:542-545, 1987.
19. Adari H, Lowy DR, Willumsen BF, et al: Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 240:518-521, 1988.
20. ras protein bind to the amino terminal regulatory domain of c-raf-1. Nature 364:308-313, 1993.
21. Moodie SA, Willumsen BM, Weber MJ, et al: Complexes of ras-GTP with raf-1 and mitogen-activated protein kinase. Science 260:1658-1661, 1993.
22. Zhang F, Strand A, Robbins D, et al: Atomic structure of the MAP kinase ERK2 at 2.3 Åresolution. Nature 367:704-711, 1994.
23. Rodriguez-Viciana P, Warne PH, Dhand R, et al: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532, 1994.
24. Scheffzek K, Ahmadian MR, Kabsch W, et al: The ras-ras GAP complex: structural basis for GTPase activation and its loss in oncogenic ras mutants. Science 227:333-338, 1997.
25. Boriak-Sjodin PA, Margarit SM, Bar-Sagi D, et al: The structural basis of the activation of Ras by SOS. Nature 394:337-343, 1998.
26. Clark J, Drugan JK, Terrell RS, et al: Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function. Proc Natl Acad Sci USA 93:1577-1581, 1996.
27. Holt KH, Kasson BG, Pessin GE: Insulin stimulation of MEK-dependent but ERK-independent SOS protein kinase. Mol Cell Biol 16:577-583, 1996.
28. Smith MR, Liu Y-L, Kim H, et al: Inhibition of serum-and ras-stimulated DNA synthesis by antibodies to phospholipase C. Science 247:1074-1077, 1990.
29. Chung DL, Brandt-Rauf PW, Weinstein IB, et al: Evidence that the ras oncogene-encoded p21 protein induces oocyte maturation via activation of protein kinase C. Proc Natl Acad Sci USA 89: 1993-1996, 1992.
30. Smith MR, Liu YL, Matthews NT, et al: Phospholipase C-1 can induced DNA synthesis by a mechanism independent of its lipase activity. Proc Natl Acad Sci USA 91:6554-6558, 1994.
31. Pincus MR, Chung DL, Dykes DC, et al: Pathways for activation of the ras-oncogene-encoded p21 protein. Ann CHn Lab Sci 22: 323-342, 1992.
32. Karin M: Regulation of activity by mitogen activated protein kinases. J Biol Chem 270:16483-16486, 1995.
33. Krengel U, Schlichting L, Scherer A, et al: Three-dimensional structures of H-ras p21 mutants: molecular basis for their ability to function as signal switch molecules. Cell 62:539-548, 1990.
34. Montano X, Jiminez A: Intracellular expression of the monoclonal anti-ras antibody Y13-259 blocks the transforming activity of ras oncogenes. Cell Growth Differ 6:597-605, 1995.
35. Khosravi-Far R. Bolski PA, Clark GJ, el al: Activation of Racl, RhoA and mitogen-activated protein kinases is required for ras transformation. Mol Cell Biol 15:6443-6453, 1995.
36. Olson MF, Ashworth A, Hall A: An essential role for Rho, Rac and cdc42 GTPases in cell cycle progression through G1. Science 269:1270-1272, 1995.
37. Clanton DJ. Lu Y, Blair DG, et al: Structural significance of the GTP-binding domain of ras p21 studied by site-directed mutagenesis. Mol Cell Biol 7:3092-3097, 1987.
38. Nemethy G, Pottle MS, Scheraga HA: Energy parameters in polypeptides. 9. Updating of geometrical parameters, nonbonded interactions and hydrogen bond interactions for the naturally occurring amino acids. J Phys Chem 87:1883-1887, 1983.
39. Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, et al: Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins Struct Funct Genet 4:31-47, 1988.
40. Ripol D, Scheraga HA: On the multiple-minima problem in the conformational analysis of polypeptides. II. An electrostatically-driven Monte Carlo method. Tests on poly-(L-alanine). Biopolymers 27:1283-1303, 1988.
41. Post CB, Brooks BR, Karplus M, et al: Molecular dynamics simulations of native and substrate-bound lysozyme. A study of the average structures and atomic fluctuations. J Mol Biol 190:455-479, 1986.
42. Monaco R, Chen JM, Chung DL, et al: Comparison of the computed three-dimensional structures of oncogenic forms of the ras-gene-encoded p21 protein with the structure of the normal (non-transforming) wild-type protein. J Protein Chem 14:457-466, 1995.
43. Monaco R, Chen JM, Friedman FK, et al: Structural effects of the binding of GTP to the wild-type and oncogenic forms of the ras-gene-encoded p21 proteins. J Protein Chem 14:721-730, 1995.
44. Liwo A, Gibson KD, Scheraga HA, et al: Comparison of the low energy conformations of an oncogenic and a non-oncogenic p21 protein, neither of which binds GDP or GTP. J Protein Chem 13: 237-251, 1994.
45. Chung DL, Brandt-Rauf PW, Murphy RB, et al: A peptide from the GAP-binding domain of the ras-p21 protein and azatyrosine block ras-induced maturation of Xenopus oocytes. Anticancer Res 11:1373-1378, 1991.
46. Amar S, Glozman A, Chung DL, et al: Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents. Cancer Chemother Pharmacol 41:79-85, 1997.
47. Chung DL, Joran A, Friedman FK, et al: Evidence that oocyte maturation induced by an oncogenic ras p21 protein and insulin is mediated by overlapping yet distinct mechanisms. Exp Cell Res 203:329-335, 1992.
48. Shindo-Okada N, Makabe O, Nagahara H, et al: Permanent conversion of mouse and human cells transformed by activated ras or raf genes to apparently normal cells by treatment with the antibiotic azatyrosine. Mol Carcinog 2:159-167, 1989.
49. Shibuya EK, Polverino AJ, Chang E, et al: Oncogenic ras triggers the activation of 42 kDa mitogen-activated protein kinase in extracts of quiescent Xenopus oocytes. Proc Natl Acad Sci USA 89: 9831-9835, 1992.
50. cdc2 Activation. Cold Spring Harbor Symp Quant Biol 56:427-435, 1991.
51. Haspel J, Dent P, Haystead T, et al: raf-induced kinases may be necessary but are not sufficient for ras-p21 protein induction of oocyte maturation. Med Sci Res 23:455-457, 1995.
52. Lee G, Ronai ZA, Pincus MR, et al: Identification of an intracellular protein that specifically interacts with photoaffinity-labeled oncogenic p21 protein. Proc Natl Acad Sci USA 86:8678-8682, 1989.
53. ras. J. Biol Chem. 271:23304-23309, 1996.
54. Adler V, Pincus MR, Brandt-Rauf PW, et al: Complexes of ras-p21 with jun-N-kinase and c-jun proteins. Proc Natl Acad Sci USA 92:10585-10589, 1995.
55. Chung D, Villafania A, Anwar K, et al: Mutual dependence of jun-N-terminal kinase and protein kinase C on the oncogenic ras-p21 protein-induced mitogenic signaling pathway. Med Sci Res 26:147-150, 1998.
56. Chen JM, Monaco R, Manolatos S, et al: Molecular dynamics on complexes of ras-p21 and its inhibitor protein, rap-1a, bound to the ras-binding domain of the raf-p74 protein. Identification of effector domains in the raf protein. J Protein Chem 16:631-635, 1997.
57. Chung D, Amar S, Glozman A, et al: Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the ras binding domain of the raf-p74 protein, identified from molecular dynamics calculations. J Protein Chem16: 619-629, 1997.